Metformin and the gastrointestinal tract
- PMID: 26780750
- PMCID: PMC4742508
- DOI: 10.1007/s00125-015-3844-9
Metformin and the gastrointestinal tract
Abstract
Metformin is an effective agent with a good safety profile that is widely used as a first-line treatment for type 2 diabetes, yet its mechanisms of action and variability in terms of efficacy and side effects remain poorly understood. Although the liver is recognised as a major site of metformin pharmacodynamics, recent evidence also implicates the gut as an important site of action. Metformin has a number of actions within the gut. It increases intestinal glucose uptake and lactate production, increases GLP-1 concentrations and the bile acid pool within the intestine, and alters the microbiome. A novel delayed-release preparation of metformin has recently been shown to improve glycaemic control to a similar extent to immediate-release metformin, but with less systemic exposure. We believe that metformin response and tolerance is intrinsically linked with the gut. This review examines the passage of metformin through the gut, and how this can affect the efficacy of metformin treatment in the individual, and contribute to the side effects associated with metformin intolerance.
Keywords: Bile acids; DPP-4; GLP-1; Gut/intestine; Lactate; Metformin; Microbiome; OCT1; Review; Serotonin; Uptake.
Figures
References
-
- Bailey CJ, Day C. Metformin: its botanical background. Pract Diabetes Int. 2004;21:115–117. doi: 10.1002/pdi.606. - DOI
-
- Inzucchi SI, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centered approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2015;58:429–442. doi: 10.1007/s00125-014-3460-0. - DOI - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
